* Vaxart Inc reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -11 cents. The mean expectation of three analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -13 cents to -8 cents per share.

* Revenue rose 134.8% to $4.93 million from a year ago; analysts expected $850.00 thousand.

* Vaxart Inc's reported EPS for the quarter was a loss of 6 cents​.

* The company reported a quarterly loss of $14.08 million.

* Vaxart Inc shares had fallen by 14.9% this quarter and gained 26.1% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 9.1% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Vaxart Inc is 4.00 This summary was machine generated from LSEG data November 14 at 04:20 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.10 -0.06 Beat

Jun. 30 2024 -0.03 -0.09 Missed

Mar. 31 2024 -0.14 -0.14 Met

Dec. 31 2023 -0.14 -0.12 Beat